Iatrogenic Factors in Psychopathology
Open accessThe DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index; 11 of the 96 sources its claims cite were checked for support.
Abstract
The side effects and risks associated with the medical intervention are defined as iatrogenesis. Adverse drug reactions, malpractice, medical error, and negligence constitute common iatrogenic complications. Examples of important syndromes induced by medications are asthma caused by beta-adrenoceptor antagonists, pulmonary fibrosis associated with cytotoxic agents, gastric bleeding and complications with anti-inflammatory agents, torsade de pointes tachycardia with various drugs, abnormal glucose homeostasis with thiazide and corticosteroids, and osteonecrosis of the jaw with bisphosphonates. \n \nIn psychiatry, iatrogenesis has traditionally been concerned with medical complications of psychotropic drug treatment, such as tardive dyskinesia and insulin resistance with antipsychotic drugs, and cardiac and metabolic disturbances with antidepressant medications. The complications may occur due to direct toxicity, drug-drug interactions, intoxication, or withdrawal from psychotropic medications. In more recent years, attention has also been dedicated to the patient experience of negative effects of psychotherapy, including the interactions between pharmacotherapy and psychotherapy. \n \nAs it happened with medical therapy, psychiatric treatment has mainly been assessed and evaluated as to its capacity to improve psychiatric symptomatology. Side effects have been conceptualized as the unavoidable drawbacks of any form of medical therapy. Little attention has been paid to the adverse psychological and behavioral effects of psychiatric treatment on psychopathology and illness course. In view of the insufficient body of knowledge on the iatrogenic effects of psychological therapies, we will only concentrate on the effects of psychotropic drug treatment. Many of the insights that have been gained in the past 25 years have originated in this journal.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 3 Not valid · 58 Not checked · 24 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Withdrawal symptoms, which may follow discontinuation of psychotropic drugs, such as benzodiazepines [36], antipsychotic medications [4,37], and antidepressant treatment [38][39][40], are also a form of behavioral toxicity.”
§ Iatrogenic Factors in Psychopathology > The Concept of Behavioral Toxicity
What the sources say
- Supportedcites [36] source
In 'Pharmacological Strategies' our copy states that administering an antidepressant on withdrawal 'may worsen the state of behavioral toxicity which is associated with withdrawal phenomena as well as other manifestations of oppositional tolerance', directly classing withdrawal under behavioral toxicity. The opening section unifies withdrawal symptoms under the oppositional model of tolerance and adds SSRI/SNRI to the drugs inducing withdrawal 'together with BZD, barbiturates, and other psychotropic drugs', and 'First Module: Explanatory Therapy' plus 'Conclusions' apply the behavioral toxicity concept to the withdrawal/loss-of-efficacy picture. The paper therefore supports the paraphrase for antidepressant discontinuation (the part this citation is offered for) and, in its general framing, for psychotropic withdrawal. (LLM, conf=0.85)
- Not checked yetcites [4] source
- Partly supportedcites [37] sourceExperimental — accuracy not yet measured
Our copy of Fava (2014) supports the antidepressant-specific part of the sentence: the Withdrawal Reactions section states that withdrawal symptoms follow discontinuation of AD treatment and are described for any type of AD, particularly SSRI, venlafaxine and duloxetine, and the Oppositional Model of Tolerance section attributes their appearance to oppositional processes when drug treatment ends. But the source frames these phenomena as adverse events 'subsumed under the rubric of tolerance' / manifestations of tolerance (Abstract, Introduction-Loss of AD Efficacy), and it nowhere uses or endorses the characterization 'behavioral toxicity' — searches for 'behavioral toxicity' and 'toxicity' returned only semantic neighbours, no exact phrase. The label 'a form of behavioral toxicity' is therefore the citing authors' framing, not this source's; the source also says nothing about benzodiazepine or antipsychotic withdrawal (carried by other citations). (LLM, conf=0.72)
- Not checked yetcites [38][39][40]
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Paradoxical reactions may also occur, such as increased agitation, excitement, insomnia, and talkativeness with benzodiazepines, particularly in children and the elderly [33].”
§ Iatrogenic Factors in Psychopathology > The Concept of Behavioral Toxicity
What the sources say
- Could not verifycites [33] sourceExperimental — accuracy not yet measured
Our copy of Chouinard et al. (2015) never mentions paradoxical reactions, talkativeness, or paediatric/elderly populations (searched: paradoxical reactions, talkativeness/excitement/disinhibition, children and elderly). Its only benzodiazepine content is the 'Rebound Symptoms' section, which describes withdrawal-emergent rebound insomnia, rebound anxiety and rebound panic after abrupt discontinuation of short/intermediate half-life benzodiazepines in adults — a different phenomenon from a paradoxical excitative reaction occurring during drug administration, so it neither supports nor contradicts the claim. The paper's scope is a proposed classification of SSRI/SNRI withdrawal (Tables 3-5, case series), which does not cover benzodiazepine paradoxical effects. (LLM, conf=0.70)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“If prodromal symptoms may have a pathophysiological role in affective disorders and some residual symptoms may progress to become prodromal symptoms of relapse, then reduction or disappearance of residual symptomatology may entail a more favorable long-term outcome of depression.”
§ Iatrogenic Factors in Psychopathology > The Changing Presentation of Psychiatric Disorders
What the sources say
- Supportedcites [20] source
The Conclusions/Evidence-Based Psychiatric Treatment opening passage states the hypothesis almost verbatim: residual symptoms' 'correlation with poor long-term outcome led to the hypothesis that residual symptoms upon recovery might progress to become prodromal symptoms of relapse and that treatment directed toward residual symptoms might yield long-term benefits.' The Sequential Treatment section reinforces it ('the preventive effects of the sequential strategy appear to be related to abatement of residual symptoms'; 'Residual symptoms are among the most powerful predictors of relapse') and the meta-analysis concludes the sequential approach 'may play a role in reducing relapse and recurrence,' i.e. a more favorable long-term outcome. Both the claim and the source keep the same hedged modality ('may'/'might'). The only clause not asserted by this paper is the antecedent about prodromal symptoms having a pathophysiological role in affective disorders, which the citing authors frame as their own conditional premise (the paper credits the prodromal-symptoms literature to Fava & Kellner 1991, reference 1); the substantive part attributed to this source — residual-to-prodromal progression and better long-term outcome from reducing residual symptomatology — is stated. (LLM, conf=0.85)
- Not checked yetcites [21] source
- Not checked yetcites [22] source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim have been checked yet.
In the paper
“According to the oppositional model of tolerance, continued drug treatment may recruit processes that oppose the initial acute effects of a drug.”
§ Iatrogenic Factors in Psychopathology > Pathophysiological Mechanisms of Behavioral Toxicity
What the sources say
- Not checked yetcites [41] source
- Not checked yetcites [42] source
- Not checked yetcites [47] source
- Could not verifycites [48] sourceExperimental — accuracy not yet measured
Our copy of Fava et al. (2014) contains no passage stating or naming the 'oppositional model of tolerance'; searches for 'oppositional model of tolerance', 'oppositional process counteracts the acute effect', and 'tolerance model drug action mechanism' returned only the iatrogenic-comorbidity sections. The closest content (Abstract, 'Iatrogenic comorbidity'/'Supersensitivity') describes dopamine receptor supersensitivity following prolonged blockade and loss of therapeutic response during long-term treatment, but frames these as withdrawal/iatrogenic phenomena credited to Chouinard and Chouinard (2008) and Fava and Offidani (2011), not as a model of tolerance opposing a drug's initial acute effects. The reference list does include Fava G.A., Offidani E. (2011) 'The mechanisms of tolerance in antidepressant action', but the body text never attributes an oppositional tolerance model to it, so our copy neither supports nor contradicts the claim. (LLM, conf=0.70)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Sequential treatment was thus able to favorably affect the long-term course of depressive illness and the longitudinal development of symptoms (rollback phenomenon).”
§ Iatrogenic Factors in Psychopathology > The Changing Presentation of Psychiatric Disorders
What the sources say
- Partly supportedcites [20] sourceExperimental — accuracy not yet measured
The meta-analysis supports the long-term-course part: the Sequential Treatment section states the findings 'lend support to the view that the sequential administration of psychotherapy after response to acute-phase pharmacotherapy ... may play a role in reducing relapse and recurrence', with significant pooled risk ratios (0.781 overall; 0.674 after discontinuation, 0.811 with continuation) and 'feasibility and favorable long-term outcome'. However, the source frames this with explicit hedging (publication bias possibly leading to overestimation, designs that 'may have produced overly optimistic results', 'may play a role'), whereas the citing sentence asserts it as achieved ('was thus able to favorably affect'). The specific element 'the longitudinal development of symptoms (rollback phenomenon)' is not supported: our copy contains no mention of a rollback phenomenon (searched 'rollback', 'psychological costs of recovery'); it only refers to 'a longitudinal view of development of disorders that can be subsumed under the staging model' and to preventive effects 'appearing to be related to' abatement of residual symptoms, which is a hedged mechanistic remark, not a demonstrated effect on symptom trajectories. (LLM, conf=0.72)
- Not checked yetcites [21] source
- Not checked yetcites [22] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
36 more claims · 3 with their cited sources checked
Create a free account to see all 90 claims and to verify the 85 references still open.
- It may state two separate claims as one. 38
- Probably not a substantial claim. 18
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hence, withdrawal symptoms that occur upon discontinuation of medications prescribed for valid medical reasons do not suggest, per se, either a substance-related (13) or an addiction disorder (6).”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New symptoms are usually the same, common to all psychotropic medications during withdrawal [12, 15, 23] (e.g., nausea, headaches, sleep disturbances) [10], but also specific and unique for a drug class (e.g., specific serotonin-related symptoms: flu-like symptoms, diarrhea, confusion) [10].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, factors such as duration and type of treatment, prior history of exposure to AD, and pharmacological manipulations such as augmenting and switch strategies, may entail very profound implications as well.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“With long-term therapy, loss of treatment efficacy and some side effects (such as increased appetite and weight gain), which did not occur initially, may then appear.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [9]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Thus, similarly to rebound anxiety, the risk seems related to benzodiazepine elimination half-life and potency [20, 23] and independent form the length of treatment [1].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [23]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Iatrogenic Factors in Psychopathology > Conclusion
“In the fifties, a sociologist, Harvey L. Smith [87], defined the psychiatrist as the marginal man of the medical profession.”
§ Iatrogenic Factors in Psychopathology > References
“86. Smith HL. Psychiatry in medicine: intra-or inter-professional relationships? Am J Sociol. 1957 Nov; 63(3): 285-9.”
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
The pre-therapeutic classification of co-morbidity in chronic disease
Feinstein, A. R. (1970) · Journal of Chronic Diseases · doi:10.1016/0021-9681(70)90054-8 · Cited by 1,544
Mechanisms of stress in the brain
McEwen, B. S., Bowles, N. P., Gray, J. D., Hill, M. N., Hunter, R. G., Karatsoreos, I. N., & Nasca, C. (2015) · Nature Neuroscience · doi:10.1038/nn.4086 · Cited by 1,386
Cuthbert, B. N. (2014) · World Psychiatry · doi:10.1002/wps.20087 · Cited by 1,377
Reed, G. M., First, M. B., Kogan, C. S., Hyman, S. E., Gureje, O., Gaebel, W., Maj, M., Stein, D. J., Maercker, A., Tyrer, P., et al. (2019) · World Psychiatry · doi:10.1002/wps.20611 · Cited by 765
X-ray structures and mechanism of the human serotonin transporter
Coleman, J. A., Green, E. M., & Gouaux, E. (2016) · Nature · doi:10.1038/nature17629 · Cited by 668
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Self-citationExploring comorbidity within mental disorders among a Danish national population
Plana-Ripoll, O., Pedersen, C. B., Holtz, Y., Benros, M. E., Dalsgaard, S., de Jonge, P., Fan, C. C., Degenhardt, L., Ganna, A., Greve, A. N., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3658 · Cited by 584
Prevention of Recurrent Depression With Cognitive Behavioral Therapy: Preliminary Findings
Fava, G. A., Rafanelli, C., Grandi, S., Conti, S., & Belluardo, P. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.9.816 · Cited by 491
Self-citationFava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Self-citationLinden, M. (2013) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.1765 · Cited by 397
Paradoxical reactions to benzodiazepines: literature review and treatment options
Mancuso, C. E., Tanzi, M. G., & Gabay, M. (2004) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.13.1177.38089 · Cited by 298
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
Cognitive behavioral treatment of residual symptoms in primary major depressive disorder
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.9.1295 · Cited by 266
Self-citationSubclinical symptoms in mood disorders: pathophysiological and therapeutic implications
FAVA, G. A. (1999) · Psychological Medicine · doi:10.1017/s0033291798007429 · Cited by 258
Self-citationMania associated with antidepressant treatment: comprehensive meta‐analytic review
Tondo, L., Vázquez, G., & Baldessarini, R. J. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01514.x · Cited by 256
Staging: a neglected dimension in psychiatric classification
Fava, G. A., & Kellner, R. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03362.x · Cited by 252
Self-citationNeuroleptic-induced supersensitivity psychosis
(1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.11.1409 · Cited by 224
Can long-term treatment with antidepressant drugs worsen the course of depression?
Fava, G. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0204 · Cited by 223
Self-citationFava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Self-citationAdult Utilization of Psychiatric Drugs and Differences by Sex, Age, and Race
Moore, T. J., & Mattison, D. R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.7507 · Cited by 207
Teff, K. L., Rickels, M. R., Grudziak, J., Fuller, C., Nguyen, H.-L., & Rickels, K. (2013) · Diabetes · doi:10.2337/db13-0430 · Cited by 195
Well-Being Therapy: Treatment Manual and Clinical Applications
Fava, G. A. (2016) · doi:10.1159/isbn.978-3-318-05822-2 · Cited by 170
Self-citationGuidi, J., Tomba, E., & Fava, G. A. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040476 · Cited by 167
Self-citationNew Classification of Selective Serotonin Reuptake Inhibitor Withdrawal
Chouinard, G., & Chouinard, V.-A. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000371865 · Cited by 164
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
Self-citationIatrogenic harm from psychological therapies—time to move on
Parry, G. D., Crawford, M. J., & Duggan, C. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.163618 · Cited by 146
The Clinical Process in Psychiatry: A Clinimetric Approach
Fava, G. A., Rafanelli, C., & Tomba, E. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06444 · Cited by 143
Self-citation(1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-75-4-651_3 · Cited by 125
The Concept of Recovery in Affective Disorders
Fava, G. A. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000289025 · Cited by 113
Self-citationCerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112
Nielsen, M., Hansen, E. H., & Gøtzsche, P. C. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03686.x · Cited by 103
Mouton, J. P., Njuguna, C. W., Kramer, N., Stewart, A., Mehta, U., Blockman, M., Smidt, M. F.-D., de Waal, R., Parrish, A., Wilson, D., et al. (2016) · Medicine · doi:10.1097/md.0000000000003437 · Cited by 98
Maslej, M. M., Bolker, B. M., Russell, M. J., Eaton, K., Durisko, Z., Hollon, S. D., Swanson, G. M., Thomson Jr., J. A., Mulsant, B. H., & Andrews, P. W. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477940 · Cited by 98
Rational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95
Self-citationOffidani, E., Fava, G. A., Tomba, E., & Baldessarini, R. J. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000345316 · Cited by 94
Self-citationFava, G. A., Guidi, J., Rafanelli, C., & Rickels, K. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000480038 · Cited by 93
Self-citationThe Intellectual Crisis of Psychiatric Research
Fava, G. A. (2006) · Psychotherapy and Psychosomatics · doi:10.1159/000092890 · Cited by 79
Self-citationEvidence-based medicine was bound to fail: a report to Alvan Feinstein
Fava, G. A. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.01.012 · Cited by 79
Self-citationDiscontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience
Fava, G. A., & Belaise, C. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000492693 · Cited by 77
Self-citationThornlow, D. K., Anderson, R., & Oddone, E. (2009) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2009.06.015 · Cited by 74
Do Antidepressant and Antianxiety Drugs Increase Chronicity in Affective Disorders?
Fava, G. A. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000288880 · Cited by 73
Self-citationWhen Discontinuing SSRI Antidepressants Is a Challenge: Management Tips
Jha, M. K., Rush, A. J., & Trivedi, M. H. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18060692 · Cited by 73
Joseph, M. F., Youngstrom, E. A., & Soares, J. C. (2008) · Future Neurology · doi:10.2217/14796708.4.1.87 · Cited by 68
Iatrogenesis: A review on nature, extent, and distribution of healthcare hazards
Peer, R., & Shabir, N. (2018) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_329_17 · Cited by 68
Subclinical Symptoms of Panic Disorder: New Insights into Pathophysiology and Treatment
Fava, G. A., & Mangelli, L. (1999) · Psychotherapy and Psychosomatics · doi:10.1159/000012345 · Cited by 62
Self-citationFava, G. A., Guidi, J., Rafanelli, C., & Sonino, N. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000366041 · Cited by 62
Self-citationCognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder
Hindmarch, I. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02085.x · Cited by 61
Rothschild, A. J., Raskin, J., Wang, C.-N., Marangell, L. B., & Fava, M. (2014) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2013.08.008 · Cited by 59
Richardson, W. S., & Doster, L. M. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.10.020 · Cited by 55
Behavioral Toxicity Revisited: Iatrogenic Comorbidity in Psychiatric Evaluation and Treatment
Fava, G. A., Cosci, F., Offidani, E., & Guidi, J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000570 · Cited by 55
Self-citationAssessing medication burden and polypharmacy: finding the perfect measure
Gnjidic, D., Tinetti, M., & Allore, H. G. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1301206 · Cited by 54
Depression Associated with Medical Illness: Treatment Considerations
Fava, G. A., & Sonino, N. (1996) · CNS Drugs · doi:10.2165/00023210-199605030-00004 · Cited by 53
Self-citationClinical Pharmacopsychology: Conceptual Foundations and Emerging Tasks
Fava, G. A., Tomba, E., & Bech, P. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000458458 · Cited by 52
Self-citationGhaemi, S. N. (2002) · doi:10.1201/b15278 · Cited by 48
More than one-third of systematic reviews did not fully report the adverse events outcome
Parsons, R., Golder, S., & Watt, I. S. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2018.12.007 · Cited by 45
Cosci, F., & Chouinard, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00007-x · Cited by 41
Grace, S. L., Medina-Inojosa, J. R., Thomas, R. J., Krause, H., Vickers-Douglas, K. S., Palmer, B. A., & Lopez-Jimenez, F. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000486794 · Cited by 39
Récalt, A. M., & Cohen, D. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000496734 · Cited by 38
International Task Force on Benzodiazepines
Balon, R., Chouinard, G., Cosci, F., Dubovsky, S. L., Fava, G. A., Freire, R. C., Greenblatt, D. J., Krystal, J. H., Nardi, A. E., Rickels, K., et al. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000489538 · Cited by 35
Self-citationHolding On: Depression, Sensitization by Antidepressant Drugs, and the Prodigal Experts
Fava, G. A. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000288992 · Cited by 33
Self-citationNeurobiologic Dimensions of Depression and Mania
Carroll, B. J. (1983) · Springer eBooks · doi:10.1007/978-3-642-69129-4_11 · Cited by 32
Emerging clinical trends and perspectives on comorbid patterns of mental disorders in research
Fava, G. A., Tossani, E., Bech, P., Berrocal, C., Chouinard, G., Csillag, C., Wittchen, H., & Rief, W. (2014) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1412 · Cited by 31
Self-citationRisks and Implications of Interrupting Maintenance Psychotropic Drug Therapy
Baldessarini, R. J. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000288950 · Cited by 30
The Medical Evaluation of Psychiatric Patients
Schiffer, R. B., Klein, R. F., & Sider, R. C. (1988) · Springer eBooks · doi:10.1007/978-1-4899-0783-7 · Cited by 22
Failure to Respond after Reinstatement of Antidepressant Medication: A Systematic Review
Bosman, R. C., Waumans, R. C., Jacobs, G. E., Oude Voshaar, R. C., Muntingh, A. D. T., Batelaan, N. M., & van Balkom, A. J. L. M. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491550 · Cited by 21
Shapiro, B. B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4995-4 · Cited by 20
Psychopathology as a science: Its scope and tasks
Lipowski, Z. J. (1966) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(66)80012-3 · Cited by 16
Challenging the promotion of antidepressants for nonsevere depression
Braillon, A., Lexchin, J., Noble, J. H., Menkes, D., M'sahli, L., Fierlbeck, K., Blumsohn, A., & Naudet, F. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13010 · Cited by 16
DiMascio, A., & Shader, R. I. (1968) · PubMed · Cited by 15
Psychiatry in Medicine: Intra- Or Inter- Professional Relationships?
Smith, H. L. (1957) · American Journal of Sociology · doi:10.1086/222220 · Cited by 15
Adverse Psychiatric Reactions to Modern Medication
Whitlock, F. A. (1981) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048678109159417 · Cited by 15
Fava, G. A., Benasi, G., & Cosci, F. (2017) · Verhaltenstherapie · doi:10.1159/000460826 · Cited by 14
Self-citationPsychiatric effects of drugs for other disorders
Parker, C. (2016) · Medicine · doi:10.1016/j.mpmed.2016.09.011 · Cited by 11
What psychologists need to know about psychotropic medications
Tomba, E., Guidi, J., & Fava, G. A. (2018) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2154 · Cited by 11
Self-citationAntipsychotic Drugs: When and How to Withdraw Them?
Falloon, I. R. H. (2006) · Psychotherapy and Psychosomatics · doi:10.1159/000091770 · Cited by 10
DiMascio, A., Dr, G., & Shader, R. I. (1968) · PubMed · Cited by 10
Medical Complications of Psychiatric Treatment
Lahijani, S. C., & Harris, K. A. (2017) · Critical Care Clinics · doi:10.1016/j.ccc.2017.03.008 · Cited by 8
Behavioral Toxicity of Psychiatric Drugs
Perl, M., Hall, R. C. W., & Gardner, E. R. (1980) · Psychiatric Presentations of Medical Illness · doi:10.1007/978-94-011-7677-4_18 · Cited by 6
Behavioral toxicity of psychotropic drugs. V. Effects on gross behavior patterns.
DiMascio, A., Shader, R. I., & Gs, H. (1969) · PubMed · Cited by 6
Should benzodiazepines be avoided?
Jørgensen, M. B., & Osler, M. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12943 · Cited by 6
Behavioral Toxicity of Nonpsychiatric Drugs
Hall, R. C. W., Stickney, S. K., & Gardner, E. R. (1980) · Psychiatric Presentations of Medical Illness · doi:10.1007/978-94-011-7677-4_19 · Cited by 4
Cited by
Allostatic load and its impact on health: A systematic review
Guidi, J., Lucente, M., Sonino, N., & Fava, G. A. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000510696 · Cited by 1,266
Self-citationAcute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
de Leon, J., Ruan, C.-J., Schoretsanitis, G., & De las Cuevas, C. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507638 · Cited by 164
Evers, A. W. M., Colloca, L., Blease, C., Gaab, J., Jensen, K. B., Atlas, L. Y., Beedie, C., Benedetti, F., Bingel, U., Büchel, C., et al. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000510738 · Cited by 114
Rhee, T. G., Shim, S. R., Manning, K. J., Tennen, H. A., Kaster, T. S., d’Andrea, G., Forester, B. P., Nierenberg, A. A., McIntyre, R. S., & Steffens, D. C. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000535665 · Cited by 102
“…and/or other psychotropic medications should be carefully considered since the medications themselves can have detrimental effects on cognitive performance due in part to withdrawal symptoms and/or other iatrogenic factors (e.g., extrapyramidal side effects affecting cognitive disturbances) [71].”
Background
Metadata
- Authors
- Fava, G. A., & Rafanelli, C.
- Affiliations
- University at Buffalo, State University of New York (US)
- University of Bologna (IT)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2019
- Volume
- 88
- Issue
- 3
- Pages
- 129-140
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2946703117
- Cited by
- 82
- References
- 84
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 10 · 2023: 16 · 2022: 7 · 2021: 14 · 2020: 22 · 2019: 5
- FWCI
- 9.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- Compagnia di San Paolo
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- iatrogenesis, psychotropic drugs, adverse drug reactions, tardive dyskinesia, antipsychotic adverse effects, antidepressant side effects, drug-drug interactions, drug withdrawal, psychopathology
- MeSH terms
- Humans, Iatrogenic Disease, Psychopathology, Psychotropic Drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.